Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sound waves help chemo reach brain tumors in early trial

NCT ID NCT04998864

Disease control Sponsor: InSightec Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small study tested whether a device using focused ultrasound can safely open the blood-brain barrier in patients with high-grade glioma (a type of aggressive brain cancer). The goal was to allow standard chemotherapy to reach the tumor more effectively. Only 3 patients were enrolled, and the study focused on safety and whether the barrier could be opened repeatedly. This is not a cure, but a way to improve existing treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

3 people

The number who actually took part.

Started

Aug 2021

Finished

Oct 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with glioblastoma brain tumor who will undergo surgical resection and chemotherapy as standard of care with temozolomide.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient is eligible for adjuvant TMZ treatment. 2. Men or women age between 18 and 80 years, inclusive. 3. Able and willing to give informed consent. 4. Grade IV glioma (GBM) confirmed Subjects 5. Karnofsky rating 70-100. 6. Able to communicate during the Exablate BBBD procedure. 7. Life expectancy of at least 3 months. Exclusion Criteria: 1. Evidence of acute intracranial hemorrhage. 2. The subject presents with severe symptoms and signs of increased intracranial pressure 3. Patients with cerebellar or brainstem tumors. 4. Patients with positive HIV status 5. Patients with brain tumors containing 1p/19q chromosomal co-deletion 6. Patient receiving bevacizumab (Avastin) therapy 7. Patients undergoing other concurrent therapies 8. Cardiac disease or unstable hemodynamics 9. Severe hypertension 10. Anti-coagulant therapy, or medications known to increase risk of hemorrhage within washout period prior to treatment 11. History of a bleeding disorder and/or coagulopathy 12. Known sensitivity to gadolinium-based contrast agents 13. Known sensitivity to ultrasound contrast agent 14. Severely impaired renal function 15. Subjects with significant liver dysfunction

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glioblastoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glioblastoma glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glioblastoma Glioma, malignant

Contacts and locations

Locations

  • CINAC-Hospital HM Puerta del Sur

    Móstoles, Madrid, 28938, Spain

  • Fondazione IRCCS Neurologico Carlo Besta

    Milan, 20133, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.